

Quantitative Research

Approximately 800 consumers who engaged in a mortgage transaction during the previous two years will participate in the quantitative phase of the research. Each copy test interview will take roughly 20–30 minutes. The estimated hours burden for the quantitative research ranges from 267 hours (800 respondents $\times$ $\frac{1}{3}$ hour per respondent) to 400 hours (800 respondents $\times$ $\frac{1}{2}$ hour per respondent).

Total

The total estimated hours burden for both phases of the study ranges from 303 hours (36 hours + 267 hours) to 454 hours (54 hours + 400 hours). The hours burden due to the qualitative focus groups (40 hours) have not been included in this estimate because the

focus groups will be completed under the current clearance.

William E. Kovacic,
General Counsel.

[FR Doc. 04–21687 Filed 9–27–04; 8:45 am]

BILLING CODE 6750–01–P

FEDERAL TRADE COMMISSION**Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules**

Section 7A of the Clayton Act, 15 U.S.C. 18a, as added by Title II of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, requires persons contemplating certain mergers or acquisitions to give the Federal Trade

Commission and the Assistant Attorney General advance notice and to wait designated periods before consummation of such plans. Section 7A(b)(2) of the act permits the agencies, in individual cases, to terminate this waiting period prior to its expiration and requires that notice of this action be published in the **Federal Register**.

The following transactions were granted early termination of the waiting period provided by law and the premerger notification rules. The grants were made by the Federal Trade Commission and the Assistant Attorney General for the Antitrust Division of the Department of Justice. Neither agency intends to take any action with respect to these proposed acquisitions during the applicable waiting period.

Trans No.	Acquiring	Acquired	Entities
Transactions Granted Early Termination—08/16/2004			
20041201	Carlyle Partners III, L.P.	Piedmont/Hawthorne Holdings, L.L.C	Piedmont/Hawthorne Holdings, L.L.C.
20041218	Tiger Key Acquisition, L.P.	KAC Mezzanine Holdings Company	KAC Mezzanine Holdings Company.
20041219	Tiger Key Acquisition, L.P.	KSS Holdings, Inc.	KSS Holdings, Inc.
20041228	TA IX L.P.	GlobeOp Financial Services S.A.	GlobeOp Financial Services S.A.
20041229	Flextronics International Ltd	Nortel Networks Corporation	Nortel Networks Limited, Nortel Networks S.A., Nortel Networks Tele. do Brasil Comercio e Servicos Ltda., Nortel Networks Tele. do Brasil Industria e Comercio Ltda., Nortel Networks UK Limited.
20041233	The Warnaco Group, Inc.	Doyle & Boissiere Fund I, LLC.	Ocean Pacific Apparel Corp.
20041236	Mervyn's Holding, LLC.	Target Corporation	Mervyn's, Mervyn's Brand.
20041238	Public Service Enterprise Group Incorporated.	TECO Energy, Inc.	TPS Holdings II, Inc.
20041240	J.M. Huber Corporation	Lehman FG, LLC.	CP Kelco ApS.
20041243	Nautic Partners V, L.P.	Francis G. Hickey, Jr.	Manhattan Digital Corporation.
20041256	West Virginia United Health System, Inc..	Gateway Regional Health System, Inc..	Gateway Regional Health System, Inc.
Transactions Granted Early Termination—08/17/2004			
20041245	Wachovia Corporation	Venturi Partners, Inc.	Venturi Partners, Inc.
20041254	ASP III Alternative Investments, L.P.	Reservoir Capital Master Fund, L.P.	RQ, LLC.
20041267	Babcock & Brown Holdings Inc.	Babcock & Brown Associates LLC. ..	Babcock & Brown Associates LLC.
20041268	Babcock & Brown Associates LLC. ..	Babcock & Brown Holdings Inc.	Babcock & Brown Holdings Inc.
20041272	The PNC Financial Services Group, Inc..	Aviation Finance Group, LLC.	Aviation Finance Group, LLC.
Transactions Granted Early Termination—08/18/2004			
20041230	Carl C. Icahn	Mylan Laboratories, Inc.	Mylan Laboratories, Inc.
20041231	James F. Dieberg	Capital Resource Lenders II, L.P.	Loan Source Funding Corporation, Small Business Loan Source, Inc.
20041242	2003 Riverside Capital Appreciation Fund, L.P..	Code, Hennessy & Simmons III, L.P.	United Central Industrial Supply Company, L.L.C.
20041244	Quad-C Partners VI, L.P.	Dubin Clark Fund II, L.P.	Universal Trailer Holdings Corp.
20041246	Western & Southern Mutual Holding Company.	Lafayette Life MIHC, Inc.	Lafayette Life MIHC, Inc.
20041248	Clayton, Dubilier & Rice Fund VI Limited Partnership.	Veolia Environnement S.A.	APIC Filter GmbH, APIC SAS, Culligan Corporation, Culligan Espana, S.A., Culligan France SAS, Culligan International (UK) Limited, Culligan Italiana, S.p.A., Culligan N.V., Culligan of Canada, Ltd., Culligan Vostok, Culligan Wassertechnik, GmbH, US Filter Argentina S.A.

Trans No.	Acquiring	Acquired	Entities
20041249	Dynamics Research Corporation	CGW Southeast Partners IV, L.P.	Impact Innovations Group LLC.
20041252	Venturi Partners, Inc.	Comsys Holding, Inc.	Comsys Holding, Inc.
20041264	Boral Limited	Ready Mixed Concrete Company (RMCC).	McKinney Concrete Products, LLC, Ready Mixed Concrete Company (RMCC), Sprat-Platte Ranch Co., LLLP.

Transactions Granted Early Termination—08/19/2004

20041183	Verizon Communications, Inc.	Qwest Communications International Inc..	Qwest Wireless L.L.C.
20041277	Joe Lewis Allbritton	Riggs National Corporation	Riggs National Corporation.

Transactions Granted Early Termination—08/20/2004

20041259	Avaya, Inc.	Spectel plc	Spectel plc.
20041271	Carlyle Europe Partners II LP	Clariant Ltd.	Clariant Corporation
20041275	ASP III Alternative Investments, L.P.	Thomas L. Phillips	Doctors' Preferred, Inc., Phillips Health, LLC.
20041279	William J. McEnery	Don H. Barden	Barden Colorado Gaming, LLC.
20041282	New Enterprise Associates 10, L.P.	Jeffrey Citron	Vonage Holdings Corporation.
20041283	Wells Fargo & Company	Colleen D. Porterfield	Bates Leasing Company, Ltd., Mile-High Deep Rock Water Company.
20041284	Wells Fargo & Company	Roxanne F. Anderson	Bates Leasing Company, Ltd., Mile-High Deep Rock Water Company.
20041285	Long Point Capital Fund, L.P.	Bank of America Corporation	Savage Sports Corporation.
20041293	Coöperatieve Centrale Raiffeisen-Boerenleenbank B.A..	Maize Acquisition Corporation	Farm Credit Services of America, FLCA; Farm Credit Services of America, PCA; Maize Acquisition Corporation; Maize Acquisition Corporation II (FLCA).
20041295	Sumner M. Redstone	SportsLine.com, Inc.	SportsLine.com, Inc.
20041299	Globix Corporation	NEON Communications, Inc.	NEON Communications, Inc.
20041301	ALLTEL Corporation	ALLTEL Coropration	Eau Claire Cellular Telephone Limited Partnership, Raleigh-Durham MSA Limited Partnership.

Transactions Granted Early Termination—08/23/2004

20041200	Carlyle Partners III, L.P.	General Electric Company	GE Engine Services—Corporate Aviation, Inc.
20041206	Medtronic, Inc.	Coalescent Surgical, Inc.	Coalescent Surgical, Inc.
20041216	Teva Pharmaceutical Industries Ltd ..	Active Biotech AB	Active Biotech AB.
20041237	Gardner Denver, Inc.	Audax Private Equity Fund, L.P.	nash_elmo Corp., nash_elmo Holdings LLC.
20041269	Madison Dearborn Capital Partners IV, L.P..	Boise Cascade Corporation	BC Brazil Investment Corporation; BC Chile Investment Corp.; BCT, Inc.; BC China Corp.; Boise Alljoist Ltd.; Boise Building Products Limited; Boise Cascade do Brasil LTDA, Dr. Lauro Azambuja; Boise Cascade Corporation Chiles, S.A.; Boise Southern Company; Canada, Minnesota, Dakota & Western Railway Company; Compania Industrial Puerto Montt, S.A.; International Falls Power Company; Minidoka Paper Company.

Transactions Granted Early Termination—08/24/2004

20041276	R.H. Donnelley Corporation	SBC Communications Inc.	APIL Partners Partnership, The Don Tech II Partnership.
20041278	R.H. Donnelley Corporation	R.H. Donnelley Corporation	The AM-DON Partnership, The Don Tech II Partnership.
0041297	Tootsie Roll Industries, Inc.	Concord Confections Inc.	Alpharetta Confections, Inc.; Concord Wax, LLC; Impel Movieline Inc.; Terra Rouge Estates Inc.
20041298	Marathon Fund Limited Partnership IV.	VFI Holdings, Inc.	Vitality Foodservice, Inc.

Transactions Granted Early Termination—08/25/2004

20041208	Flextronics International Ltd.	Northfield Acquisition Co.	Northfield Acquisition Co.
----------------	-------------------------------------	---------------------------------	----------------------------

Trans No.	Acquiring	Acquired	Entities
20041239	Regal-Beloit Corporation	General Electric Company	GE Industrial Systems Mexico LP, GE Industrial Systems Technology Management, Inc.
Transactions Granted Early Termination—08/26/2004			
20041250	The Garfield Weston Charitable Foundation.	Graeme R. Hart	Burns, Philp Inc.
20041260	The Garfield Weston Charitable Foundation.	Mr. Graeme R. Hart	Tone Bros. Inc.
20041262	The Sherwin-Williams Company	Bessemer Securities LLC.	Paint Sundry Brands Corporation.
20041302	ALLTEL Corporation	Telephone and Data Systems, Inc., Voting Trust.	Georgia RSA #12 Partnership.
Transactions Granted Early Termination—08/27/2004			
20040902	The Sherwin-Williams Company	Duron, Inc.	Duron, Inc.
20041291	SLM Corporation	Helios Education Foundation	Southwest Student Services Cor- poration.
20041306	Bruckmann, Rosser, Sherrill & Co. II, L.P..	SPC Partners II, L.P.	Totes Acquisition Corporation.
20041307	CGW Southeast Partners IV, L.P.	TRP Investors LP	TruckPro, Inc.
20041308	Citigroup Inc.	Knight Trading Group, Inc.	Knight Execution Partners LLC, Knight Financial Products LLC.
20041310	KKR Millennium Fund L.P.	DLJ Merchant Banking Partners III, L.P..	Jostens Holding Corp.
20041320	General Electric Company	W.D. Company, Inc.	Dillard Asset Funding Company, Dil- lard Credit Card Master Trust I, Dillard National Bank, Dillard's, Inc.
Transactions Granted Early Termination—09/01/2004			
20041289	FedEx Corporation	Quad/Graphics, Inc.	Parcel Direct/DDU, Inc., Parcel Di- rect DDU, LLC, Parcel/Direct, Inc., Parcel Direct Logistics, Inc., Parcel Direct, LP.
20041304	Caterpillar Inc.	Remy International, Inc.	Williams Technologies, Inc.
20041318	Mr. Bryan Gentry	L'Air Liquide SA	GT&S, LP.
20041323	Alvarion Ltd	interWAVE Communications Inter- national Inc..	interWAVE Communications Inter- national, Inc.
Transactions Granted Early Termination—09/02/2004			
20041255	Symbol Technologies, Inc.	Matrics, Inc.	Matrics, Inc.
Transactions Granted Early Termination—09/03/2004			
20041261	Raytheon Company	Photon Research Associates, Inc.	Photon Research Associates, Inc.
20041327	Banco Santander Central Hispano, S.A..	Abbey National plc	Abbey National plc.
20041330	DEI Holdings, Inc.	Sanford M. Gross	Definitive Technology, LLP.
20041339	Marquee Holdings, Inc.	AMC Entertainment Inc.	AMC Entertainment Inc.
20041341	Macquarie Infrastructure Assets Trust.	Macquarie Bank Limited	Macquarie District Energy Holdings LLC, North America Capital Hold- ings Company.
20041351	Tekelec	Steleus Group, Inc.	Steleus Group, Inc.
20041359	Caroline Hunt Trust Estate	BMC Industries, Inc.	P.T. Vision-Ease Asia, Vision-Ease Canada Ltd., Vision-Ease Lens Europe Ltd., Vision-Ease Lens, Inc.
Transactions Granted Early Termination—09/07/2004			
20041135	General Dynamics Corporation	Thyssen-Bornemieza Continuity Trust.	TriPoint Global Communications Inc.
20041326	Encore Medical Corporation	MPI Holdings, LLC.	Empi, Inc.
20041338	Green Field II, LLC.	MMM Healthcare, Inc.	MMM Healthcare, Inc.
Transactions Granted Early Termination—09/08/2004			
20041317	The Children's Place Retail Stores, Inc..	The Walt Disney Company	TDS Franchising, LLC, The Disney Store, LLC.
20041336	The McGraw-Hill Companies, Inc.	Capital IQ, Inc.	Capital IQ, Inc.

Trans No.	Acquiring	Acquired	Entities
20041348	AGL Resources Inc.	American Electric Power Company, Inc..	Jefferson Island Storage & Hub L.L.C.
20041349	Ainsworth Lumber Co., Ltd	Potlatch Corporation	Potlatch Corporation.
20041355	HKW Capital Partners II, L.P.	Maxon Corporation	Maxon Corporation.
Transactions Granted Early Termination—09/09/2004			
20041322	Michael E. Heisley, Sr	Ivaco Inc.	Ifastgroupe and Company, Limited Partnership, Ifastgroupe Realty Inc., IFC (Fasteners) Inc.
Transactions Granted Early Termination—09/10/2004			
20041292	The Pepsi Bottling Group, Inc.	Seltzer & Rydholm, Inc.	Seltzer & Rydholm, Inc.
20041311	Merck & Co., Inc.	DOV Pharmaceutical, Inc.	DOV Pharmaceutical Inc.

FOR FURTHER INFORMATION CONTACT:

Sandra M. Peay, Contact Representative; or Renee Hallman, Case Management Assistant, Federal Trade Commission, Premerger Notification Office, Bureau of Competition, Room H-303, Washington, DC 20580, (202) 326-3100.

By Direction of the Commission

Donald S. Clark,

Secretary.

[FR Doc. 04-21688 Filed 9-27-04; 8:45 am]

BILLING CODE 6750-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2004N-0045]

Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Health and Diet Survey—2004 Supplement

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Health and Diet Survey—2004 Supplement" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT:

Peggy Robbins, Office of Management Programs (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1223.

SUPPLEMENTARY INFORMATION: In the *Federal Register* of May 19, 2004 (69 FR 28928), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and

a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-0545. The approval expires on September 30, 2007. A copy of the supporting statement for this information collection is available on the Internet at <http://www.fda.gov/ohrms/dockets>.

Dated: September 22, 2004.

Jeffrey Shuren,

Assistant Commissioner for Policy.

[FR Doc. 04-21674 Filed 9-27-04; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2004E-0023]

Determination of Regulatory Review Period for Purposes of Patent Extension; REYATAZ

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) has determined the regulatory review period for REYATAZ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.

ADDRESSES: Submit written comments and petitions to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to <http://www.fda.gov/dockets/ecomments>.

FOR FURTHER INFORMATION CONTACT:

Claudia V. Grillo, Office of Regulatory Policy (HFD-013), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 240-453-6699.

SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417) and the Generic Animal Drug and Patent Term Restoration Act (Public Law 100-670) generally provide that a patent may be extended for a period of up to 5 years so long as the patented item (human drug product, animal drug product, medical device, food additive, or color additive) was subject to regulatory review by FDA before the item was marketed. Under these acts, a product's regulatory review period forms the basis for determining the amount of extension an applicant may receive.

A regulatory review period consists of two periods of time: A testing phase and an approval phase. For human drug products, the testing phase begins when the exemption to permit the clinical investigations of the drug becomes effective and runs until the approval phase begins. The approval phase starts with the initial submission of an application to market the human drug product and continues until FDA grants permission to market the drug product. Although only a portion of a regulatory review period may count toward the actual amount of extension that the Director of Patents and Trademarks may award (for example, half the testing phase must be subtracted as well as any time that may have occurred before the patent was issued), FDA's determination of the length of a regulatory review period for a human drug product will include all of the testing phase and approval phase as specified in 35 U.S.C. 156(g)(1)(B).

FDA recently approved for marketing the human drug product REYATAZ (atazanavir sulfate). REYATAZ is indicated in combination with other